Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03890614 · ClinicalTrials.gov registry record
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
A clinical trial of Hematologic Malignancy, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT03890614 is a study of Hematologic Malignancy that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03890614, a study of Hematologic Malignancy, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
Conditions Studied
Interventions
- OTHER Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03890614
The ClinicalTrials.gov registry entry for NCT03890614 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (69% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates is the first listed.
NCT03890614 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03890614 about?
NCT03890614 is a clinical study titled "Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity". The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidan...
What is the current status of trial NCT03890614?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2019-05-16. Estimated completion is 2027-02.
What conditions does trial NCT03890614 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT03890614?
The interventions under investigation include: Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates (OTHER).
Who is sponsoring clinical trial NCT03890614?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03890614 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.